Articles related to Oncology, Radiation

The discovery of I-NCMs’ ability to simultaneously patrol blood vessels and infiltrate tumor environments opens new possibilities for treating therapy-resistant cancers.

Workplace exposure to harmful chemicals remains a significant risk factor for bladder cancer, particularly affecting specific occupations and requiring targeted prevention strategies.

Durvalumab consolidation therapy demonstrated unprecedented survival benefit in limited-stage SCLC, extending median overall survival by nearly two years compared to placebo.

Poor metabolizers of UGT1A1 face a significantly increased risk of severe neutropenia from irinotecan therapy, making genetic testing crucial for appropriate dose modification.

Among patients with early-stage triple-negative breast cancer, the addition of pembrolizumab to standard chemotherapy demonstrated a 4.9 percentage point improvement in 5-year overall survival.

The case highlights the critical importance of thorough documentation and appropriate follow-up care, regardless of a patient’s age or statistical likelihood of serious conditions.